All In Biotech

Investigational drug · Phase 3

Efruxifermin

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

6

Any phase or sponsor naming "Efruxifermin"

First trial start

2023

Nov 10, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Efruxifermin", any sponsor or status.

Conditions studied

As listed on its trial records.

  • NASH - Nonalcoholic Steatohepatitis
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis
  • NASH/MASH
  • NAFLD/MASLD
  • NASH With Fibrosis
  • MASH With Fibrosis

Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Efruxifermin" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 49 on PubMed

Also in development for NASH - Nonalcoholic Steatohepatitis

  • IVA337LanifibranorPhase 31 trial

    Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis

  • efocipegtrutideHM15211Phase 21 trial

    Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis

  • SNP-610Phase 21 trial

    Sinew Pharma Inc. · NASH - Nonalcoholic Steatohepatitis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.